Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr 10;6(2):100419.
doi: 10.1016/j.xhgg.2025.100419. Epub 2025 Feb 21.

Male proband with intractable seizures and a de novo start-codon-disrupting variant in GLUL

Affiliations
Case Reports

Male proband with intractable seizures and a de novo start-codon-disrupting variant in GLUL

Elizabeth Carbonell et al. HGG Adv. .

Abstract

Bi-allelic variants in GLUL, encoding glutamine synthetase and responsible for the conversion of glutamate to glutamine, are associated with a severe recessive disease due to glutamine deficiency. A dominant disease mechanism was recently reported in nine females, all with a de novo single-nucleotide variant within the start codon or the 5' UTR of GLUL that truncates 17 amino acids of the protein product, including its critical N-terminal degron sequence. This truncation results in a disorder of abnormal glutamine synthetase stability and manifests as a phenotype of severe developmental and epileptic encephalopathy. Here, we report the first male with a pathogenic de novo variant in the same critical region of GLUL, with a phenotype of refractory focal and generalized seizures, as well as developmental delays. We provide a detailed description of the disease course and treatment response.

Keywords: 5'UTR; GLUL; de novo; glutamine synthetase; seizures; start codon; start-loss.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.O’D.L. was a paid consultant to Tome Biosciences, Ono Pharma USA, Addition Therapeutics, and Congenica and receives research funding from Pacific Biosciences. H.L.R. has received rare disease research funding from Microsoft and Illumina and compensation as a past member of the scientific advisory board of Genome Medical.

Figures

Figure 1
Figure 1
GLUL locus and the impact of the c.-13-2A>G splice-disrupting 5'UTR variant (A) Schematic of GLUL locus. The location of the spice-disrupting variant in GLUL, c.-13-2A>G (red), in the 5′ UTR non-coding region upstream of exon 2 is depicted. Two degron sequences (yellow) fall between the canonical start codon Met1 (green) and the downstream alternative in-frame start codon Met18 (green) from which translation is reinitiated. Two RNA transcript isoforms are detected in the proband, 56% with normal splice pattern (purple) and 44% with aberrant splice pattern (orange) due to the c.-13-2A>G variant. The resulting protein is truncated at the 5′ end, removing the degron sequence required to regulate glutamine synthetase degradation by the proteasome and leading to impaired regulation of glutamine level. (B) Whole-blood RNA-seq analysis. The top shows RNA-seq from normalized GTEx blood samples. The middle shows whole-blood RNA-seq from the male RGP proband. Orange line depicts the novel splice junction created by the c.-13-2A>G variant, truncating exon 2. Purple lines depict known splice junctions. The bottom shows the MANE Select transcript (GenBank: NM_001033044, GenCode: ENST00000331872) with the positions of Met1 and Met18 indicated in green, where the first 26 bases are not present in 44% of the RNA-seq reads, consistent with a heterozygous casual variant. E, exon; Met, methionine.

Similar articles

References

    1. Wojcik M.H., Reuter C.M., Marwaha S., Mahmoud M., Duyzend M.H., Barseghyan H., Yuan B., Boone P.M., Groopman E.E., Délot E.C., et al. Beyond the exome: What’s next in diagnostic testing for Mendelian conditions. Am. J. Hum. Genet. 2023;110:1229–1248. - PMC - PubMed
    1. Schot R., Ferraro F., Geeven G., Diderich K.E.M., Barakat T.S. Re-analysis of whole genome sequencing ends a diagnostic odyssey: Case report of an RNU4-2 related neurodevelopmental disorder. Clin. Genet. 2024;106:512–517. doi: 10.1111/cge.14574. - DOI - PubMed
    1. Li Q., Agrawal R., Schmitz-Abe K., Genetti C.A., Fernandes M.A., Fryou N.L., Madden J.A., Brownstein C.A., Smith E.C., Rajabi F., et al. Reanalysis of clinical exome identifies the second variant in two individuals with recessive disorders. Eur. J. Hum. Genet. 2023;31:712–715. - PMC - PubMed
    1. Mørup S.B., Nazaryan-Petersen L., Gabrielaite M., Reekie J., Marquart H.V., Hartling H.J., Marvig R.L., Katzenstein T.L., Masmas T.N., Lundgren J., et al. Added Value of Reanalysis of Whole Exome- and Whole Genome Sequencing Data From Patients Suspected of Primary Immune Deficiency Using an Extended Gene Panel and Structural Variation Calling. Front. Immunol. 2022;13 - PMC - PubMed
    1. Susgun S., Kesim Y., Khalilov D., Sirin N.G., Gezegen H., Salman B., Yucesan E., Gokcay G., Korbeyli H.K., Balci M.C., et al. Reanalysis of exome sequencing data reveals a treatable neurometabolic origin in two previously undiagnosed siblings with neurodevelopmental disorder. Neurol. Sci. 2023;44:2527–2540. - PubMed

Publication types